disease 2019 (COVID-19) is an infectious respiratory disease caused
by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
previously referred to as "2019 novel coronavirus."1
has not studied the use of olanzapine long-acting injection in
patients with COVID-19 nor in patients at risk of contracting
should use their clinical judgment in determining the most
appropriate approach in treating a patient with olanzapine
long-acting injection who has confirmed or suspected COVID-19.
should be exercised in patients with low leukocyte and/or neutrophil
counts for any reason, in patients
medicines known to cause neutropenia, in patients with
a history of drug-induced bone marrow depression/toxicity,
bone marrow depression caused by concomitant illness, radiation
therapy or chemotherapy and
hypereosinophilic conditions or with myeloproliferative disease.2
has been reported commonly when olanzapine and valproate are used
addition, please note the following common adverse events (≥ 1/100
to < 1/10) that may occur in patients being treated with
olanzapine pamoate. The following list includes adverse reactions
observed from spontaneous reporting and in clinical trials. For full
list of undesirable effects, please refer to section 4.8 of the
ZypAdhera Summary of Product Characteristics.
(common) (As assessed by measured values from clinical trials in the
Olanzapine Integrated Database.)2
the most current information regarding the coronavirus, please refer
to the websites of local health authorities and/or the WHO website at
Coronavirus disease (COVID-19) outbreak.
World Health Organization. Naming the coronavirus disease (COVID-19)
and the virus that causes it.
Accessed March 11, 2020.
ZypAdhera [summary of product characteristics] Eli Lilly Netherland
B.V., The Netherlands.
= The Center for Disease Control
= Eli Lilly and Company
= World Health Organization